|
Variable
|
Type 2 diabetes patients [n = 100]
|
Age and sex matched controls [n = 47]
|
p value
|
|---|
|
Age [years]
|
63.0 ± 11.6
|
58.4 ± 14.6
|
0.0589
|
|
Duration of diabetes [years]
|
13.7 ± 10.3
|
–
|
–
|
|
Chromogranin A [ng/mL] a
|
57.80 ± 34.74
|
49.97 ± 22.29
|
0.1587
|
|
Chromogranin B [ng/mL]
|
99.72 ± 54.79
|
112.54 ± 61.68
|
0.1698
|
|
HbA1C [%]
|
7.3 ± 1.2
|
–
|
–
|
|
HbA1C [mmol/mol]
|
56.0 ± 13.1
|
–
|
–
|
|
White blood cell count [109/L]
|
7.93 ± 2.08
|
7.21 ± 1.91
|
0.0443
|
|
Red blood cell count [1012/L]
|
4.82 ± 0.39
|
5.01 ± 0.56
|
0.0389
|
|
eGFR [mLmin−1(1.73m2)−1]
|
83.49 ± 17.84
|
90.19 ± 13.13
|
0.0117
|
|
Body mass index (BMI) [kg/m2]
|
31.1 ± 5.8
|
27.9 ± 5.4
|
0.0017
|
|
Sex (Female / Male)
|
50: 50
|
24: 23
|
1.0000
|
|
Hypertension
|
91
|
17
|
< 0.0001
|
|
Thyroid disease
|
16
|
4
|
0.3038
|
|
Gastroesophageal reflux disease
|
31
|
5
|
0.0074
|
|
Antacid therapy
|
29
|
3
|
0.0013
|
- Values are expressed as mean ± standard deviation, unit of anamnestic data is the number of observations
- eGFR Estimated glomerular filtration rate, HbA1C Glycated hemoglobin
- aExcluding the measurement of study subjects, who had any condition leading to chromogranin A elevation [3, 4, 7]. Remaining number of observations was 64 and 43, respectively
